Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Buys $21,945.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 1,500 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was bought at an average cost of $14.63 per share, for a total transaction of $21,945.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,536,102 shares of the company’s stock, valued at approximately $80,993,172.26. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Snehal Patel also recently made the following trade(s):

• On Monday, August 5th, Snehal Patel purchased 5,500 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $13.18 per share, with a total value of $72,490.00.
• On Tuesday, July 23rd, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $15.89 per share, for a total transaction of $23,835.00.

Greenwich LifeSciences Trading Down 1.2 %

GLSI stock opened at $14.15 on Monday. The stock’s 50 day simple moving average is $14.46 and its 200 day simple moving average is $15.06. Greenwich LifeSciences, Inc. has a 12-month low of $7.58 and a 12-month high of $21.44. The stock has a market capitalization of $182.25 million, a PE ratio of -19.65 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.20). On average, research analysts predict that Greenwich LifeSciences, Inc. will post -0.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upped their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd.

Institutional Trading of Greenwich LifeSciences

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers bought a new position in Greenwich LifeSciences during the second quarter valued at approximately $117,000. Bank of New York Mellon Corp purchased a new stake in Greenwich LifeSciences during the 2nd quarter valued at $264,000. Finally, Vanguard Group Inc. raised its stake in Greenwich LifeSciences by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 223,102 shares of the company’s stock valued at $4,449,000 after buying an additional 1,420 shares during the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.